胶质母细胞瘤术后甲氨蝶呤间质化疗同步放化疗临床观察  

Clinical observation on simultaneous sadiotherapy and chemotherapy of methotrexate interstitial chemotherapy after glioblastoma

作　　者：李丰展 盖立平 杨艳敏 麻来峰 LI Fengzhan;GE Liping;YANG Yanmin;MA Laifeng(The Third People's Hospital of Henan Province,Zhengzhou 450000,China)

机构地区：[1]河南省直第三人民医院,河南郑州450000

出　　处：《中国实用神经疾病杂志》2020年第17期1544-1548,共5页Chinese Journal of Practical Nervous Diseases

基　　金：河南省教育厅项目(编号:19B320017)。

摘　　要：目的观察间质化疗在胶质母细胞瘤患者救治中的作用。方法90例胶质母细胞患者分为间质化疗组(A组)42例,术后仅进行常规放化疗治疗(B组)48例,对2组患者肿瘤复发时间、中位生存时间及3 a存活率进行分析。结果A组肿瘤复发时间(13.61±3.83)月、中位生存时间2.10(1.35~2.70)a;B组肿瘤复发时间(10.31±2.20)月,中位生存时间1.55(1.30~2.10)a,差异均有统计学意义(P<0.05)。结论间质化疗在胶质母细胞瘤中的治疗效果优于常规放化疗治疗。Objective To explore the clinical value of interstitial chemotherapy in the treatment of glioblastoma patients.Methods The clinical data of 90 patients with glioblastoma were divided into interstitial chemotherapy group(hereinafter referred to as A group)of 42 cases and B group(hereinafter referred to as B group)of 48 cases.Results The recurrence time was(13.61±3.83)months and the median survival time was 2.10(1.35-2.70).The tumor recurrence time was(10.31±2.20)months and the median survival time was 1.55(1.30-2.10)years in the group without interstitial chemotherapy(B).There was a difference in statistical analysis between the two groups,P<0.05.Conclusion The treatment effect of interstitial chemotherapy for glioblastoma is better than that of non-interstitial chemotherapy.

关 键 词：胶质母细胞瘤 甲氨蝶呤 替莫唑胺 间质化疗 预后 

分 类 号：R739.41[医药卫生—肿瘤]